A recent YouGov poll commissioned by clinical trials startup Lindus Health from the UK found that a significant percentage of respondents across different age groups, including 18-24-year-olds (36%) and 25-49-year-olds (30%), expressed interest in trialing psilocybin and other currently illegal substances like ketamine, MDMA, and DMT for treating mental health conditions, as reported by Psychedelic Spotlight.
These findings are evidence of the changing attitudes toward psychedelic treatments, and it seems that more people under 50 years of age are now open to trying them.
Prevalence of Psychedelic Use
The survey commissioned by Lindus Health found that one-third of respondents under 50 years old are open to psychedelic mental health treatments. The survey also revealed a broad spectrum of interest in different types of psychedelics, with psilocybin being the most popular. Other substances, such as ketamine, DMT, and MDMA, were also mentioned by the participants.
The survey results showed that the majority of respondents were open to trying psychedelics for mental health treatments. This is a stark contrast to previous generations when psychedelics were stigmatized and seen as dangerous substances.
These findings demonstrate how attitudes towards psychedelics are changing and suggest that these substances could be more widely accepted. As public opinion evolves, more people could be open to trying psychedelics for mental health treatments and gaining access to their potential benefits.
Another survey results show an overall growing acceptance of psychedelic treatment options among Americans. This is further evident from the findings of a study conducted by The Harris Poll and Delic Holdings Corp, which revealed that 65% of Americans with mental health conditions want access to psychedelics for their therapy.
This data indicates that there’s an increasing amount of support for the use of psychedelic therapies in mental health treatment, with more people now feeling comfortable trying them.
The current legal status of psychedelics varies widely depending on which substance is being referenced. For example, ketamine is an FDA-approved anesthetic and can be prescribed for a variety of ailments by licensed clinicians. Psilocybin, however, like cannabis, is still considered a Schedule 1 drug in the eyes of the federal government, making its sale and use illegal.
Potential Benefits of Psychedelics
The potential benefits of psychedelics for mental health treatment are vast. Research has shown that psychedelics can activate the Default Mode Network (DMN) in the brain, which is responsible for our automatic thoughts and daydreaming processes. Activating this network can lead to increased creativity and introspection, which is beneficial for those suffering from mental health conditions such as depression, anxiety, and PTSD.
A study conducted in 2016 also showed that a single dose of psilocybin produced substantial and enduring decreases in depressed mood and anxiety, along with increases in quality of life and decreases in death anxiety among cancer patients. The overall rate of clinical response at six months on clinician-rated depression and anxiety was 78% and 83%, respectively. This study is further evidence of the potential for psychedelics to be used as a therapeutic tool in treating mental health conditions.
The data from the YouGov survey and other studies suggest that this is a new age for psychedelic therapy, with more people under 50 years of age being open to trying them. While further research needs to be conducted on their potential benefits, these findings indicate that there is a strong interest in using psychedelics for mental health treatments.
The results also show that a majority of Americans now support access to psychedelic therapies, suggesting that there is potential for wide-reaching health and mental wellness benefits if these substances are used correctly. It’s possible that in the future, psychedelics will become more widely accepted as effective treatments for mental disorders. As attitudes continue to change and public opinion evolves, it could be the start of a new era for psychedelic therapies.